Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4Unknown 3Completed 3Active not recruiting 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4NET 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Squamous Cell Carcinoma of Head and Neck 37Nasopharyngeal Carcinoma 27Lung Neoplasms 25Uterine Cervical Neoplasms 22Biliary Tract Neoplasms 22Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 18Head and Neck Neoplasms 17Cholangiocarcinoma 16Urinary Bladder Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Ovarian Neoplasms 13Esophageal Neoplasms 12Carcinoma 12Colorectal Neoplasms 11Stomach Neoplasms 10Small Cell Lung Carcinoma 10Carcinoma, Transitional Cell 8Mouth Neoplasms 7Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Recurrence 6Nasopharyngeal Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Bile Duct Neoplasms 5Peritoneal Neoplasms 4

Interventions

Cisplatin 4Etoposide 3atezolizumab 2Drug Therapy 2Carboplatin 2tivozanib 1repotrectinib 1lutetium Lu 177 dotatate 1durvalumab 1dostarlimab 1belinostat 1Somatostatin 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Ipilimumab 1FOLFOXIRI protocol 1EC regimen 1DLL3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Neuroendocrine × Cisplatin × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04325425 2025-09-30

FOLFIRINEC

Centre Hospitalier Universitaire Dijon

Phase 2 Recruiting
218 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT04268121 2025-07-23

NEONEC

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Recruiting
78 enrolled
EndocrineGastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT06372626 2024-06-14

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Recruiting
93 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡